Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease. - Wikidata - awgldk - TriplyDB

Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.

Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.

http://www.wikidata.org/entity/Q36366340

about

Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics New Era of Lipid-Lowering Drugs The emerging role of apolipoprotein C-III: beyond effects on triglyceride metabolism Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?Apolipoproteins A-I, B, and C-III and Obesity in Young Adult Cherokee.ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease Coronary heart disease risks associated with high levels of HDL cholesterol Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Mapping O-glycosylation of apolipoprotein C-III in MALDI-FT-ICR protein profiles.Racial differences between African-American and white women in insulin resistance and visceral adiposity are associated with differences in apoCIII containing apoAI and apoB lipoproteins.HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients.APOL1 G1 genotype modifies the association between HDLC and kidney function in African Americans Triglycerides on the rise: should we swap seats on the seesaw?Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results Kernel machine testing for risk prediction with stratified case cohort studies.Divergent pathway of lipid profile components for cardiovascular disease and mortality events: Results of over a decade follow-up among Iranian population.Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond APOC3 induces endothelial dysfunction through TNF-α and JAM-1 Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Robust risk prediction with biomarkers under two-phase stratified cohort design.The effect of a low-fat, plant-based lifestyle intervention (CHIP) on serum HDL levels and the implications for metabolic syndrome status - a cohort study.Impact of variants in CETP and apo AI genes on serum HDL cholesterol levels in men and women from the Polish population Looking into the crystal ball-upcoming drugs for dyslipidemia.Novel metabolic biomarkers of cardiovascular disease.Dysfunctional HDL and atherosclerotic cardiovascular disease.New and emerging biomarkers in cardiovascular disease.Key differences between apoC-III regulation and expression in intestine and liver.Identifying new Risk Markers and Potential Targets: The Value of the Proteome.Apolipoprotein C-III Nanodiscs Studied by Site-Specific Tryptophan Fluorescence.Associations of anthropometry and lifestyle factors with HDL subspecies according to apolipoprotein C-III.Diabetes and dyslipidemia: characterizing lipoprotein metabolism.HDL Subspecies Defined by Presence of Apolipoprotein C-III and Incident Coronary Heart Disease in Four Cohorts.ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1.N-(3-Benzoylphenyl)-1H-Indole-2-Carboxamide decreases triglyceride levels by downregulation of Apoc3 gene expression in acute hyperlipidemic rat model.Using primary murine intestinal enteroids to study dietary TAG absorption, lipoprotein synthesis, and the role of apoC-III in the intestine.Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk.

P2860

Q26774903-F91A1A18-2ACD-4104-9425-F14805F71916 Q28072298-B31FA745-1AA5-4536-94B7-1213731DBD0C Q28072835-BB5E7167-634A-4705-9739-1B321F672DB0 Q28077776-A3A41945-10C3-42E6-807B-89170F170BFC Q33572201-BE97FD0C-A382-4B50-AF90-350F8007C271 Q33725659-69F9BA6B-140D-44E0-A181-FAAD126F3E6D Q34238727-B5A1BD13-90CB-4BA8-8717-A0C58F0DDB9A Q34297247-536C3862-4A5D-4FA0-AA5D-A4D57622E83E Q34441411-83B335E7-7AD0-4465-BA08-D79B7582EA8A Q34555445-8EBA2F88-926B-4164-B482-9C24BE4B4935 Q34793857-7B858299-8220-4D63-9C06-E7D9A783E7DB Q35027220-35D984A5-DE95-4651-B820-44CB2B889985 Q35646631-BFF0072D-BCA1-410C-9A09-8C8C9D777173 Q35753514-6377EEF8-F810-4808-8AA0-1EBE57860009 Q35915137-76DF4FF7-9A9C-42C5-8230-F5D22B917F2C Q36144245-D7C54697-D1BB-4321-B209-8B9B882BDBB7 Q36731776-0203641B-7F11-4A2F-9AC3-678CEA32D9EE Q36984250-884EFBCA-74F5-4AFB-B9E6-FA78D147AB59 Q37035438-D35C209D-CE88-4354-AC6F-746190809DD3 Q37162996-A740A691-7E7E-4252-812F-D3A57E1C69F4 Q37251472-BF294A74-09F1-428E-9C1F-DCC46B8A017E Q37254899-356729DD-5487-4F23-8A41-B3496B574AAB Q37302661-37076AE3-17A8-4B27-AD71-43C8148C44A2 Q37361819-E9672973-C272-4C8E-8858-D2A420D791F0 Q37412661-0579B516-EC5F-49DE-B8A6-E94B9367B13A Q38235611-769B2EA4-CEBD-4783-8028-D9174B98D711 Q38245327-8843DE01-F952-471C-B473-2E294675CA1F Q38577283-945E4F9C-0BDC-4102-80DB-86F3FC284287 Q38586900-FDE4B434-B26C-4A01-AB8B-A10569A3FAC5 Q38664013-0B4CC976-2D9F-4875-B198-8C3B659DCCEA Q38756916-113A7A59-1198-4957-A953-4E7C2090EA67 Q39485969-4F18ECE8-3D18-483D-840F-4A4A2072F559 Q40263801-7DD497FD-6306-466C-A208-15444F347190 Q41283425-EC8B0527-5397-40B7-8E5E-93F0879F4E8A Q49834367-9551B65B-BE40-4139-90BF-CB8601C11C88 Q50075898-8AD6EC86-4D7C-4B25-900A-2B89AECA9E05 Q51017649-C3CF28D7-70FB-4869-B1CC-CC0F86A7B3E6 Q51113879-84C25504-7640-4073-91F9-423384532C62 Q51153525-7B98F218-6852-4526-9AA0-06A9F1285390 Q52375183-6985A01C-267E-4FD8-9C69-949D2A659D6F

P2860

Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease.

http://www.wikidata.org/entity/Q36366340

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.

@ast

Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.

@en

type

label

Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.

@ast

Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.

@en

prefLabel

Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.

@ast

Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.

@en

P1433

Q36366340-51749B0C-A4AB-489E-B0C1-DCC128543266

P1476

Q36366340-ADDDAAA5-D20C-415C-9A1C-40BAD15A781D

P2093

Q36366340-03FDA085-FE29-471D-9812-5C8AE730DA1C

Q36366340-59FFAE72-298C-4CA5-B4E8-AB4F3EE00A6A

P2860

Q36366340-0D53B8BB-C300-44E4-82A5-20BB139B6411

Q36366340-12E59918-5230-4C9E-BE6D-567AFA71EEDC

Q36366340-17501E64-9BBE-4762-AEB7-DD3B2A304A9F

Q36366340-18387BCB-B8E7-4C48-BCCB-38E609613706

Q36366340-216DB4F1-E05C-4F06-B66B-F587B07A6E83

Q36366340-31F7AC3A-FC35-49DB-B526-44B96644A57E

Q36366340-38EEE622-D87C-4A40-BE19-901F22CF15DA

Q36366340-391B3BDF-7F8B-4AA9-A53D-A163324B3061

Q36366340-39CF816B-03AE-4F5D-A54A-47442D28889D

Q36366340-3D2B5C24-A7CA-4C0D-876B-07FFD8352203

P31

Q36366340-A3B284B5-5394-4659-B300-437EA487B2AF

P356

Q36366340-FC89D8A7-0ADB-445F-8E6C-D934AB1DB6D3

P433

Q36366340-453C5247-4C93-43D9-AE3A-9A1B0CFF92A3

P478

Q36366340-F93ED1C4-6DE6-47DC-852C-BFD0CADBAB44

P50

Q36366340-4CB63489-00D5-4E43-8508-72DC6C7B3973

Q36366340-E9604BFB-B7A7-4FEA-81E0-2E3721191105

P577

Q36366340-D01A3008-5B8A-47C1-B2B4-0BC553AC34C7

P698

Q36366340-A4527B2B-538D-4070-893C-D8A6FE7B5099

P932

Q36366340-E4A3F020-6999-4129-B4FC-9EFEB6EC77BA

P356

JAHA.111.000232

P1433

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease

P1476

Apolipoprotein C-III as a Pote ...... cident Coronary Heart Disease.

@en

P2093

Frank M Sacks

http://www.w3.org/2001/XMLSchema#string

Jeremy D Furtado

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway

Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL

Structure and dynamics of human apolipoprotein CIII

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study

Effect of torcetrapib on the progression of coronary atherosclerosis

Effects of torcetrapib in patients at high risk for coronary events

Dysfunctional HDL as a diagnostic and therapeutic target

Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function.

Associations of the HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

P31

scholarly article

P356

10.1161/JAHA.111.000232

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Majken K Jensen

P577

2012-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23130121

http://www.w3.org/2001/XMLSchema#string

P932

3487368

http://www.w3.org/2001/XMLSchema#string